- Price
- $378.00
- Day
- -1.25%
- Mkt Cap
- $81.98B
- 52W Range
- $273.71 – $436.24
- Volume
- 828.7K
- Beta
- 0.68
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Bank of America Corp DE lifted its stake in Elevance Health, Inc. (NYSE: ELV) by 23.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,718,766 shares of the company's stock after buying an additional 511,626 shares during the period.
Read full article
Axiom Investment Management LLC bought a new position in Elevance Health, Inc. (NYSE: ELV) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,853 shares of the company's stock, valued at approximately $542,000. Other institutional investors have also recently
Read full article
INDIANAPOLIS--(BUSINESS WIRE)--Cancer care is often overwhelming, not just medically, but emotionally and logistically. Elevance Health is strengthening its connected cancer care model to enhance support consumers receive throughout their care journeys, with a focus on earlier support, personalized care navigation, and more coordinated care.Each year in the U.S., 1.8 million people are diagnosed with cancer. For many patients, a cancer diagnosis brings not only medical decisions, but also a comp.
Read full article
Amundi increased its stake in shares of Elevance Health, Inc. (NYSE: ELV) by 145.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,693,664 shares of the company's stock after purchasing an additional 1,597,497 shares during the period. Amundi owned 1.24%
Read full article
Delta Air Lines was a contributor during the quarter. Fuel prices spiked in March following the onset of the Iran War, creating a near-term headwind for airline profitability. Intercontinental Exchange stock price declined due to market concerns about AI disruption and potential competition from new exchanges launching perpetual futures. We were pleased to initiate a position in Equitable Holdings at a meaningful discount to intrinsic value.
Read full article
Tech stocks are dragging the Nasdaq lower while the Federal Reserve kicks off a critical policy meeting, and one major CEO just spent a million dollars buying into a stock the market punished after earnings.
Read full article
Seth Klarman's Baupost Group rarely shows its cards, so when the latest 13F filing (holdings as of March 31, 2026, filed May 14, 2026) disclosed his five largest long common-stock positions, the disclosure read like a treasure map.
Read full article
Bessemer Group Inc. lessened its stake in shares of Elevance Health, Inc. (NYSE: ELV) by 97.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,297 shares of the company's stock after selling 138,897 shares during the quarter. Bessemer Group Inc.'s
Read full article
Shares of Elevance Health, Inc. (NYSE: ELV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-three ratings firms that are covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average
Read full article
Acumen Wealth Advisors LLC decreased its stake in shares of Elevance Health, Inc. (NYSE: ELV) by 51.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,935 shares of the company's stock after selling 7,357 shares during the quarter. Acumen Wealth Advisors
Read full article
US equities advanced during Q2, supported by another quarter of better-than-expected corporate earnings and continued enthusiasm for companies benefiting from artificial intelligence-related investment. Our bottom five contributors to return in Q2 were Accenture, CME Group, Salesforce, Boston Scientific and EOG Resources. Our top five contributors to return in Q2 were Texas Instruments, Lam Research, NXP Semiconductors, Elevance Health and Alphabet.
Read full article
The purchase of 1,000 shares at $366.05 per share represents a total capital commitment of $366,050. This transaction increased the director's total direct equity position by 10% relative to his pre-trade holdings.
Read full article